Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:
NCT01222780
First received: October 15, 2010
Last updated: May 26, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)